Article

Enhanced anti-tumor effects through continuous administration of engineered CAR-macrophages derived from pluripotent stem cell-derived myeloid cell lines

2024-07-23

Abstract excerpt

Even after chimeric antigen receptor (CAR)-based immunotherapy has dramatically changed therapeutic approaches for malignancies, balancing therapeutic efficacy with labor and financial cost remains a major problem for immunotherapy. Current study developed a cost-effective and enhanced approach to chimeric antigen receptor (CAR)-macrophage therapy for cancer and demonstrated its therapeutic effects by repeated adm...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6f6f3491-1342-5cb5-93f8-693df422403a
DOI: 10.1101/2024.07.22.604686

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Enhanced anti-tumor effects through continuous administration of engineered CAR-macrophages derived from pluripotent stem cell-derived myeloid cell linesDOI 10.1101/2024.07.22.604686Read

Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapiesSemantic proximity Read

Large-scale generation of IL-12 secreting macrophages from human pluripotent stem cells for cancer therapySemantic proximity Read

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.Semantic proximity Read

Homology-independent targeted insertion-mediated derivation of M1-biased macrophages harbouring Megf10 and CD3ζ from human pluripotent stem cellsSemantic proximity Read

Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages.Semantic proximity Read

CAR-Engineered Human Hematopoietic Stem Cell Macrophages Control Solid TumorsSemantic proximity Read

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapySemantic proximity Read

CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentationSemantic proximity Read

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptorSemantic proximity Read

Chimeric antigen receptors that trigger phagocytosisSemantic proximity Read

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responsesSemantic proximity Read

Phenotypic comparison and the potential antitumor function of immortalized bone marrow-derived macrophages (iBMDMs)Semantic proximity Read